India and Uzbekistan Launch Landmark Pharmaceutical & Nutraceutical Trade Corridor, Unlocking Access to a USD 10 Billion Eurasian Market

Why in News?

The Ministry of Health of the Republic of Uzbekistan, Nutrify Today, and Pharma Eurasia 2026 have formalised a structured Indo–CIS pharmaceutical and nutraceutical trade corridor.

The initiative positions Uzbekistan as a gateway for Indian pharma and nutraceutical exports to CIS and Eurasian markets.

Key Points

The corridor aims to strengthen healthcare trade between India and CIS countries.

Pharma Eurasia 2026 will act as the commercial execution platform for the initiative.

It integrates policy facilitation, industry leadership, and a trade exhibition platform.

Market Opportunity:

CIS dietary supplements market: Over USD 5.8 billion annually.

CIS + Eurasia nutraceutical market: Estimated USD 7–10 billion.

Growth Drivers:

Increasing adoption of preventive healthcare.

Expansion of pharmacy and retail chains in Russia, Central Asia, and the Caucasus.

Stronger regulatory frameworks favouring certified products.

Rising demand for vitamins, botanicals, and functional nutrition.

Uzbekistan as a Regional Pharma Hub:

Development of Pharma Parks and industrial clusters.

Foreign Direct Investment (FDI) facilitation in pharmaceutical manufacturing.

Regulatory modernisation aligned with international standards.

Strategic location connecting India, Russia, and Central Asia.

Dual-City Trade Architecture:

Mumbai Platform:

Hosted in Mumbai through the Sumflex & C-Suite Summit.

Focus on:

Global leadership dialogue

Investment discussions

Policy coordination among CEOs, regulators, and investors.

Tashkent Platform:

Hosted in Tashkent through Pharma Eurasia 2026.

Focus on:

Trade agreements

Regulatory collaboration

Market integration with CIS countries.

Pharma Eurasia 2026

Dates: 20–22 May 2026

Venue: Tashkent, Uzbekistan

Participants

Pharmaceutical and nutraceutical manufacturers

Ingredient and excipient suppliers

Contract manufacturers and CDMOs

Regulatory authorities

Distributors and trade buyers across CIS and Eurasia.

Key Focus Areas of the Corridor

Regulatory harmonisation between India and CIS markets.

Supply chain digitisation and documentation standardisation.

Bilateral investment and joint venture frameworks.

Clinical research and R&D collaboration.

Institutional trade matchmaking and market access facilitation.